Slynd is NOT appropriate for inducing menses in functional hypothalamic amenorrhea and should be discontinued
Slynd (drospirenone) is a progestin-only contraceptive pill that suppresses ovarian function—it will not restore spontaneous menses in FHA and may actually mask the underlying problem. 1
Why Slynd Failed and What This Means
Slynd is designed as a contraceptive that works by suppressing the hypothalamic-pituitary-ovarian (HPO) axis. In FHA, the HPO axis is already suppressed due to stress, energy deficit, or excessive exercise. Using oral contraceptives (including progestin-only pills like Slynd) for the sole purpose of regaining menses is explicitly recommended AGAINST by the 2017 Endocrine Society guidelines 2. These medications:
- Do not restore normal endogenous hormonal fluctuations
- Mask the return of spontaneous menses
- Provide no benefit for bone mineral density (the primary health concern in FHA)
- Allow continued bone loss if the underlying energy deficit persists 2
The FDA label confirms that amenorrhea is an expected side effect of Slynd, with scheduled bleeding decreasing from 81% in Cycle 1 to only 26% by Cycle 13 1. This patient's lack of response is entirely predictable.
The Correct Management Approach
First-Line Treatment: Address the Root Cause
The primary recommendation is to correct the energy imbalance through behavioral modification 2. This requires:
Nutritional intervention: Increase caloric intake by approximately 350 kcal/day above current consumption, targeting energy availability of ≥30 kcal/kg fat-free mass/day 3, 4
Body composition goals: Aim for body fat percentage >22%; each 1 kg increase in fat mass increases likelihood of menstruation by 8% 4
Exercise modification: Reduce training intensity or volume (not complete cessation) 2
Psychological support: Screen for and address psychological stressors through cognitive behavioral therapy, which has been shown to restore ovulation in 20 weeks even without weight gain 2
Expected Timeline
Menstrual function typically returns within 1-12 months of appropriate intervention, though recovery may require weight gain of approximately 2.0 kg above the weight at which menses stopped 2, 3
If Hormonal Therapy is Needed
If menses do not return after a reasonable trial (typically 3-6 months) of nutritional, psychological, and exercise interventions, the guideline recommends transdermal estradiol (100 mcg) with cyclic oral progestin (medroxyprogesterone 2.5 mg daily for 10 days/month)—NOT oral contraceptives or ethinyl estradiol 2.
This approach:
- Provides physiologic estrogen replacement
- Improves bone mineral density (unlike OCPs)
- Doesn't suppress IGF-I (a bone-trophic hormone that OCPs downregulate)
- Has demonstrated significant BMD increases at 6,12, and 18 months in adolescents with anorexia nervosa 2
Critical Pitfalls to Avoid
- Do not continue Slynd or switch to another OCP—this perpetuates the problem
- Do not focus solely on body weight—body composition (specifically fat mass) is more relevant 4
- Do not ignore underlying eating disorders or excessive exercise—these require specific intervention 2
- Do not delay bone density assessment—obtain baseline DXA if amenorrhea has persisted ≥6 months 2
Additional Considerations
Screen for overlapping PCOS, as up to 50% of patients with non-hyperandrogenic PCOS phenotype may actually have FHA 2. These patients may never resume regular menses with weight gain alone and require different management.
Counsel the patient that irregular menses during recovery are normal and do not require immediate evaluation, though conception can occur before the first menstrual period returns 2.